Prostate Cancer

What Is Finasteride? Finasteride is a prescription medication that treats benign prostatic hyperplasia (BPH) under the brand name Propecia and male-pattern hair loss under the brand name Proscar. It is part of a class of medications known as 5-alpha-reductase inhibitors. Finasteride works by decreasing the amount of hormone dihydrotestosterone (DHT) in your body. By reducing DHT, finasteride can help prevent the prostate from growing larger. It can also increase hair growth and decrease hair loss on your head. Finasteride is an oral medication available in tablet form. It is available under two brand names and formulations for separate indications: Propecia 1-milligram (mg) tablet for BPH and Proscar 5-milligram tablet for male-pattern hair loss. There is also a generic version. Drug Facts Generic Name : Finasteride Brand Name(s) : Propecia, Proscar Drug Availability : Prescription Therapeutic Classification : 5-alpha reductase inhibitor Availa

This week, save on brands such as Cozy Earth, Em John and more. These deals are only available while supplies last, so be sure to shop now. Find all of Tory's exclusive offerings for "GMA" viewers at 40Boxes.com and remember to check back throughout the week, as new items are added daily. Deal details: 1. Use the links provided below on the date(s) listed to receive the savings. 2. All deals are available only while supplies last. 3. Deals cannot be combined with other coupons and offers. 4. Shipping rates indicated are valid in the continental United States only. NEED HELP? CONTACT TORY: If you need assistance with a deal, please email help@40boxes.com. The 40 Boxes team will respond to all viewer emails within two hours during standard business hours. By clicking on these shopping links, visitors will leave Goodmorningamerica.com. These e-commerce sites are operated under different terms and privacy policies than Goodmorningamerica.com. ABC will receive a commission fo

Histological variants of oral squamous cell carcinoma (OSCC) include verrucous, basaloid, spindle cell, adenosquamous, papillary, and acantholytic types. Clear-cell changes in OSCC are rare. We report a case of a 65-year-old male Chinese patient who presented with a swelling in the lower-left mandible for three weeks, causing ill-fitting of his lower denture and an ulcer on the floor of the mouth. Histologically, the lesion showed a dense proliferation of malignant tumor cells arranged in islands and sheets consisting of squamoid cells intermixed with signet ring-shaped clear cells. The clear cells were negative for mucicarmine, periodic acid Schiff (PAS), periodic acid Schiff-diastase (PAS-D), and alcian blue (AB). Immunohistochemistry showed the tumor cells were immuno-positive for cytokeratin (CK) and p63, but CK7, CK20, and S100 were immuno-negative. Therefore, a metastatic tumor in the oral cavity was suggested. However, the CT scan did not show any primary tumors in

Global 55 100 000 (43 100 000 to 69 300 000) 2500 (1960 to 3120) 94 000 000 (73 200 000 to 118 000 000) 2480 (1940 to 3090) 70·5% (68·6 to 72·7) −0·770% (−1·56 to 0·0912) Central Europe, eastern Europe, and central Asia 9 830 000 (7 770 000 to 12 300 000) 4890 (3900 to 6000) 12 200 000 (9 670 000 to 15 200 000) 4800 (3840 to 5910) 23·8% (20·2 to 27·4) −1·86% (−4·30 to 0·410) Central Asia 511 000 (394 000 to 664 000) 2550 (1980 to 3240) 754 000 (579 000 to 994 000) 2590 (2020 to 3310) 47·7% (39·7 to 56·1) 1·71% (−1·33 to 4·70) Armenia 35 500 (26 500 to 46 700) 2540 (1930 to 3300) 46 400 (35 100 to 60 800) 2600 (1980 to 3380) 30·5% (20·8 to 40·6) 2·28% (−4·22 to 8·84) Azerbaijan 58 300 (43 600 to 78 400) 2530 (1920 to 3320) 100 000 (75 900 to 134 000) 2590 (1980 to 3380) 72·3% (57·7 to 87·3) 2·53% (−4·50 to 8·83) Georgia 77 600 (65 300 to 90 800) 2970 (2520 to 3460) 74 400 (63 300 to 86 600) 3050 (2610 to 3540) −4·24% (−10·6 to 2·61) 2·61% (−3·85 to 9·58) Kazakhstan 117 000 (88 200 to 15